USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.38 | $-0.44 | $-0.36 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $970.00K | $4.00 | $0.00 |
Inmune Bio, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 3 | $-0.50 | $-0.55 | $-0.43 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 3 | $-1.65 | $-1.77 | $-1.56 |
| Dec 2022 | 3 | $-2.36 | $-2.68 | $-2.12 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.50 | $-0.42 | $-0.43 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-1.65 | $-1.40 | $-1.42 |
| Dec 2022 | 0 / 0 | $-2.36 | $-2.04 | $-2.09 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 3 | $970.00K | $0.00 | $2.90M |
| Dec 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.38 | - | - |
| Aug 4, 2021 | Jun 2021 | $-0.34 | $-0.44 | -29.41% |
| May 5, 2021 | Mar 2021 | $-0.27 | $-0.32 | -17.09% |
| Mar 4, 2021 | Dec 2020 | $-0.31 | $-0.26 | 15.45% |
| Nov 5, 2020 | Sep 2020 | $-0.17 | $-0.36 | -108.70% |
| Aug 5, 2020 | Jun 2020 | $-0.23 | $-0.20 | 13.04% |
| May 14, 2020 | Mar 2020 | $-0.21 | $-0.19 | 9.52% |
| Mar 11, 2020 | Dec 2019 | $-0.25 | $-0.22 | 12.00% |
| Nov 8, 2019 | Sep 2019 | $-0.19 | $-0.28 | -44.85% |
| Aug 9, 2019 | Jun 2019 | $-0.20 | $-0.04 | 80.00% |
| May 15, 2019 | Mar 2019 | $-0.19 | $-0.20 | -5.26% |
| Mar 29, 2019 | Dec 2018 | $-0.19 | $-0.21 | -10.53% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $-1.09 | $-1.01 | - |
| Mar 11, 2020 | Dec 2019 | $-0.79 | $-0.74 | - |
| Mar 29, 2019 | Dec 2018 | - | $-0.21 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $970.00K | - | - |
| Aug 4, 2021 | Jun 2021 | $0.00 | $4.00 | - |
| May 5, 2021 | Mar 2021 | $4.00K | $4.00K | 1.00% |
| Mar 4, 2021 | Dec 2020 | $0.00 | $10.92K | - |
| Nov 5, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 5, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 14, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 11, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 8, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 9, 2019 | Jun 2019 | $80.00K | $0.00 | - |
| May 15, 2019 | Mar 2019 | $170.00K | $0.00 | - |
| Mar 29, 2019 | Dec 2018 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $0.00 | $10.92K | - |
| Mar 11, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 29, 2019 | Dec 2018 | - | $0.00 | - |
INMB's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 3 analysts, the average EPS estimation for Inmune Bio, Inc's next quarterly earnings is $-0.38, with a low EPS estimation of $-0.43, and a high estimation of $-0.28.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.38, the last 2 month trend is $-0.31, and the 3 month trend is $-0.32.
Based on 3 analysts, the average revenue estimation is $970.00K, with a low revenue estimation of $0.00, and a high estimation of $2.90M.
Inmune Bio, Inc's previous earnings date was Aug 4, 2021 for its fiscal quarter ended Jun 30, 2021.
INMB's earnings per share (EPS) was $-0.44, missing the consensus analysts forecast of $-0.34 by -29.41%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 37.50%, and lower than the same period a year before (Jun 2020) by 120.00%.
Revenues were $4.00.
The company reported a net income of $-6.66M.Free cash flow for the quarter was $-20.71M , compared to $-5.09M last quarter and $-1.82M a year before.
INMB ended the quarter with $14.49M in total debt, an increase of 10324.46% compared to the previous quarter, and an increase of 9409.12% compared to the same quarter a year before.
Inmune Bio, Inc's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.
INMB's earnings per share (EPS) was $-1.01, beating the consensus analysts forecast of $-1.09 by -7.34% , and lower than the previous year's EPS (Dec 2019) by 36.49%.
Revenues were $10.92K.
The company reported a net income of $-12.10M.
Inmune Bio, Inc reported a free cash flow of $-8.94M for its fiscal year, compared to $-5.38M a year ago.
The company ended the fiscal year with $160.16K in total debt, a decrease of -4.92% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
